References
- Anderson, K. (2016), gsDesign: Group Sequential Design. R package version 3.0-1. URL: https://CRAN.R-project.org/package=gsDesign
- Bonferroni, C. 1936. Teoria statistica delle classi e calcolo delle probabilita’. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commericiali di Firenze 8:3–62.
- Bretz, F., W. Maurer, W. Brannath, and M. Posch. 2009. A graphical approach to sequentially rejective multiple test procedures’. Statistics in Medicine 28 (4):586–604. doi:https://doi.org/10.1002/sim.3495.
- Burman, C.-F., C. Sonesson, and O. Guilbaud. 2009. ‘A recycling framework for the construction of Bonferroni-based multiple tests’. Statistics in Medicine 28 (5):739–761. doi:https://doi.org/10.1002/sim.3513.
- Burman, C.-F., and V. Lisovskaja. 2010. ‘The dual test: Safeguarding p-value combination tests for adaptive designs’. Statistics in Medicine 29 (7–8):797–807. doi:https://doi.org/10.1002/sim.3704.
- Cohen, A. T., R. A. Harrington, S. Z. Goldhaber, D. Russell, B. W. Wiens, A. G. Gold, A. F. Hernandez, and C. M. Gibson. 2016. ‘Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients’. New England Journal of Medicine 375 (6):534–544. doi:https://doi.org/10.1056/NEJMoa1601747.
- Dmitrienko, A., A. C. Tamhane, and F. Bretz. 2009. Multiple Testing Problems in Pharmaceutical Statistics. New York: Chapman & Hall/CRC.
- Dunnett, C. W. 1955. ‘A multiple comparison procedure for comparing several treatments with a control’. Journal of the American Statistical Association 50 (272):1096–1121. doi:https://doi.org/10.1080/01621459.1955.10501294.
- European Medicines Agency (2017), Guideline on the evaluation of anticancer medicinal products in man. Accessed on June 17, 2021. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf
- Food and Drug Administration (2018), Clinical trial endpoints for the approval of cancer drugs and biologics - Guidance for industry. Accessed on June 17, 2021. URL: https://www.fda.gov/media/71195/download
- Food and Drug Administration (2020), Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control - Guidance for industry. Accessed on June 17, 2021. URL: https://www.fda.gov/media/135936/download
- Fu, Y. 2018. ‘Step-down parametric procedures for testing correlated endpoints in a group-sequential trial’. Statistics in Biopharmaceutical Research 10 (1):18–25. doi:https://doi.org/10.1080/19466315.2017.1369898.
- Genz, A., and F. Bretz. 2009. Computation of multivariate normal and t probabilities, lecture notes in statistics. Heidelberg: Springer-Verlag.
- Glimm, E., W. Maurer, and F. Bretz. 2010. ‘Hierarchical testing of multiple endpoints in group-sequential trials’. Statistics in Medicine 29 (2):219–228. doi:https://doi.org/10.1002/sim.3748.
- Gou, J., A. C. Tamhane, D. Xi, and D. Rom. 2014. A class of improved hybrid Hochberg–Hommel type step-up multiple test procedures. Biometrika 101 (4):899–911. doi:https://doi.org/10.1093/biomet/asu032.
- Gou, J., and D. Xi. 2019. Hierarchical testing of a primary and a secondary endpoint in a group sequential design with different information times. Statistics in Biopharmaceutical Research 101 (4):398–406. doi:https://doi.org/10.1080/19466315.2018.1546613.
- Hampson, L. V., and C. Jennison. 2013. ‘Group sequential tests for delayed responses’. Journal of the Royal Statistical Society. Series B, Statistical Methodology 75:3–54. doi:https://doi.org/10.1111/j.1467-9868.2012.01030.x.
- Heerspink, H., B. Stefánsson, R. Correa-Rotter, G. Chertow, T. Greene, -F.-F. Hou, J. Mann, J. McMurray, M. Lindberg, P. Rossing et al. 2020. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 383(15):1436–1446. doi:https://doi.org/10.1056/NEJMoa2024816.
- Hochberg, Y. 1988. ‘A sharper Bonferroni procedure for multiple tests of significance.’. Biometrika 75 (4):800–802. doi:https://doi.org/10.1093/biomet/75.4.800.
- Holm, S. 1979. ‘A simple sequentially rejective multiple test procedure’. Scandinavian Journal of Statistics 6:65–70.
- Hommel, G. 1988. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75 (2):383–386. doi:https://doi.org/10.1093/biomet/75.2.383.
- Hung, J., S. J. Wang, and R. O’Neill. 2007. ‘Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials’. Journal of Biopharmaceutical Statistics 17 (6):1201–1210. doi:https://doi.org/10.1080/10543400701645405.
- Jennison, C., and B. W. Turnbull. 2000. Group sequential methods with applications to clinical trials. New York: Chapman & Hall/CRC.
- Lan, K. K. G., and D. L. DeMets. 1983. ‘Discrete sequential boundaries for clinical trials’. Biometrika 70 (3):659–663. doi:https://doi.org/10.2307/2336502.
- Li, H., J. Wang, X. Luo, J. Grechko, and C. Jennison. 2018. ‘Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance’. Biometrical Journal 60 (5):893–902. doi:https://doi.org/10.1002/bimj.201700231.
- Magirr, D., T. Jaki, and J. Whitehead. 2012. A generalised Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 99:2:494–501. doi:https://doi.org/10.1093/biomet/ass002.
- Maurer, W. 1995. ‘Multiple comparisons in drug clinical trials and preclinical assays: A-priori ordered hypothesis’. Biomed. Chem.-Pharm. Ind 6:3–18.
- Maurer, W., and F. Bretz. 2013. ‘Multiple testing in group sequential trials using graphical approaches’. Statistics in Biopharmaceutical Research 5 (4):311–320. doi:https://doi.org/10.1080/19466315.2013.807748.
- Öhrn, F., and C. Jennison. 2010. ‘Optimal group sequential designs for simultaneous testing of superiority and non-inferiority’. Statistics in Medicine 29:743–759. doi:https://doi.org/10.1002/sim.3790.
- Olshansky, B., D. L. Bhatt, M. Miller, P. G. Steg, E. A. Brinton, T. A. Jacobson, S. B. Ketchum, J. R. T. Doyle, R. A. Juliano, L. Jiao et al. 2021. ‘REDUCE-IT interim: Accumulation of data across prespecified interim analyses to final results’. European Heart Journal-Cardiovascular Pharmacotherapy. 7(3):e61–e63. doi:https://doi.org/10.1093/ehjcvp/pvaa118.
- Perkovic, V., M. J. Jardine, B. Neal, S. Bompoint, H. J. Heerspink, D. M. Charytan, R. Edwards, R. Agarwal, G. Bakris, S. Bull et al. 2019. ‘Canagliflozin and renal outcomes in type 2 diabetes and nephropathy’. New England Journal of Medicine. 380(24):2295–2306. doi:https://doi.org/10.1056/NEJMoa1811744.
- Pocock, S., D. Wang, L. Wilhelmsen, and C. H. Hennekens. 2005. The data monitoring experience in the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal 149 (5):939–943. doi:https://doi.org/10.1016/j.ahj.2004.10.038.
- Proschan, M. A., K. K. G. Lan, and J. T. Wittes. 2006. Statistical monitoring of clinical trials: A unified approach. New York: Springer.
- R Core Team (2017), R: A language and environment for statistical computing, R foundation for statistical computing, Vienna, Austria. URL: https://www.R-project.org/
- Spiessens, B., and M. Debois. 2010. ‘Adjusted significance levels for subgroup analyses in clinical trials’. Contemporary Clinical Trials 31 (6):647–656. doi:https://doi.org/10.1016/j.cct.2010.08.011.
- Tamhane, A. C., C. R. Mehta, and L. Liu. 2010. ‘Testing a primary and a secondary endpoint in a group sequential design’. Biometrics 66 (4):1174–1184. doi:https://doi.org/10.1111/j.1541-0420.2010.01402.x.
- Tang, D., and N. Geller. 1999. ‘Closed testing procedures for group sequential clinical trials with multiple endpoints’. Biometrics 55:1188–1192. doi:https://doi.org/10.1111/j.0006-341X.1999.01188.x.
- Whitehead, J. 1992. ‘Overrunning and underrunning in sequential clinical trials’. Controlled Clinical Trials 13 (2):106–121. doi:https://doi.org/10.1016/0197-2456(92)90017-T.
- Wolbers, M., E. Glimm, and D. Xi. 2019. ‘Step-down parametric procedures for testing correlated endpoints in a group-sequential trial by Yiyong Fu’. Statistics in Biopharmaceutical Research 11:104–105. doi:https://doi.org/10.1080/19466315.2018.1529614.
- Xi, D., and A. C. Tamhane. 2015. ‘Allocated recycled significance levels in group sequential procedures for multiple endpoints’. Biometrical Journal 66:90–107. doi:https://doi.org/10.1002/bimj.201300157.
- Ye, Y., A. Li, B. Yao, and B. Yao. 2013. ‘A group sequential Holm procedure with multiple primary endpoints’. Statistics in Medicine 32 (7):1112–1124. doi:https://doi.org/10.1002/sim.5700.
- Zinman, B., C. Wanner, J. M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. E. Johansen, H. J. Woerle et al. 2015. ‘Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes’. New England Journal of Medicine. 373(22):2117–2128. doi:https://doi.org/10.1056/NEJMoa1504720.